Publication:
The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications

dc.contributor.authorBrunklaus, Andreas
dc.contributor.authorBrünger, Tobias
dc.contributor.authorFeng, Tony
dc.contributor.authorFons, Carmen
dc.contributor.authorLehikoinen, Anni
dc.contributor.authorPanagiotakaki, Eleni
dc.contributor.authorVintan, Mihaela
dc.contributor.authorSymonds, Joseph
dc.contributor.authorAndrew, James
dc.contributor.authorArzimanoglou, Alexis
dc.contributor.authorDelima, Sarah
dc.contributor.authorGallois, Julie
dc.contributor.authorHanrahan, Donncha
dc.contributor.authorLesca, Gaetan
dc.contributor.authorMacLeod, Stewart
dc.contributor.authorMarjanovic, Dragan
dc.contributor.authorMcTague, Amy
dc.contributor.authorNuñez, Noemi
dc.contributor.authorPérez, Eduardo
dc.contributor.authorPerry, Michael
dc.contributor.authorPysden, Karen
dc.contributor.authorRuss, Sophie
dc.contributor.authorScheffer, Ingrid
dc.contributor.authorSully, Krystal
dc.contributor.authorSyrbe, Steffen
dc.contributor.authorVaher, Ulvi
dc.contributor.authorVelayutham, Murugan
dc.contributor.authorVogt, Julie
dc.contributor.authorWeiss, Shelly
dc.contributor.authorWirrell, Elaine
dc.contributor.authorZuberi, Sameer
dc.contributor.authorLal, Dennis
dc.contributor.authorMøller, Rikke
dc.contributor.authorMantegazza, Massimo
dc.contributor.authorCestèle, Sandrine
dc.date.accessioned2023-03-31T15:36:15Z
dc.date.available2023-03-31T15:36:15Z
dc.date.issued2022
dc.description.abstractBrain voltage-gated sodium channel NaV1.1 (SCN1A) loss-of-function variants cause the severe epilepsy Dravet syndrome, as well as milder phenotypes associated with genetic epilepsy with febrile seizures plus. Gain of function SCN1A variants are associated with familial hemiplegic migraine type 3. Novel SCN1A-related phenotypes have been described including early infantile developmental and epileptic encephalopathy with movement disorder, and more recently neonatal presentations with arthrogryposis. Here we describe the clinical, genetic and functional evaluation of affected individuals. Thirty-five patients were ascertained via an international collaborative network using a structured clinical questionnaire and from the literature. We performed whole-cell voltage-clamp electrophysiological recordings comparing sodium channels containing wild-type versus variant NaV1.1 subunits. Findings were related to Dravet syndrome and familial hemiplegic migraine type 3 variants. We identified three distinct clinical presentations differing by age at onset and presence of arthrogryposis and/or movement disorder. The most severely affected infants (n = 13) presented with congenital arthrogryposis, neonatal onset epilepsy in the first 3 days of life, tonic seizures and apnoeas, accompanied by a significant movement disorder and profound intellectual disability. Twenty-one patients presented later, between 2 weeks and 3 months of age, with a severe early infantile developmental and epileptic encephalopathy and a movement disorder. One patient presented after 3 months with developmental and epileptic encephalopathy only. Associated SCN1A variants cluster in regions of channel inactivation associated with gain of function, different to Dravet syndrome variants (odds ratio = 17.8; confidence interval = 5.4-69.3; P = 1.3 × 10-7). Functional studies of both epilepsy and familial hemiplegic migraine type 3 variants reveal alterations of gating properties in keeping with neuronal hyperexcitability. While epilepsy variants result in a moderate increase in action current amplitude consistent with mild gain of function, familial hemiplegic migraine type 3 variants induce a larger effect on gating properties, in particular the increase of persistent current, resulting in a large increase of action current amplitude, consistent with stronger gain of function. Clinically, 13 out of 16 (81%) gain of function variants were associated with a reduction in seizures in response to sodium channel blocker treatment (carbamazepine, oxcarbazepine, phenytoin, lamotrigine or lacosamide) without evidence of symptom exacerbation. Our study expands the spectrum of gain of function SCN1A-related epilepsy phenotypes, defines key clinical features, provides novel insights into the underlying disease mechanisms between SCN1A-related epilepsy and familial hemiplegic migraine type 3, and identifies sodium channel blockers as potentially efficacious therapies. Gain of function disease should be considered in early onset epilepsies with a pathogenic SCN1A variant and non-Dravet syndrome phenotype.
dc.description.versionVersión publicada
dc.identifier.citationBrunklaus A, Brünger T, Feng T, Fons C, Lehikoinen A, Panagiotakaki E, Vintan MA, Symonds J, Andrew J, Arzimanoglou A, Delima S, Gallois J, Hanrahan D, Lesca G, MacLeod S, Marjanovic D, McTague A, Nuñez-Enamorado N, Perez-Palma E, Scott Perry M, Pysden K, Russ-Hall SJ, Scheffer IE, Sully K, Syrbe S, Vaher U, Velayutham M, Vogt J, Weiss S, Wirrell E, Zuberi SM, Lal D, Møller RS, Mantegazza M, Cestèle S. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain. 2022 Nov 21;145(11):3816-3831. doi: 10.1093/brain/awac210
dc.identifier.doihttps://doi.org/10.1093/brain/awac210
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7217
dc.language.isoen
dc.subjectSCN1A
dc.subjectGain of function
dc.subjectEpilepsy
dc.subjectArthrogryposis
dc.subjectMovement disorder
dc.titleThe gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceBrain : a journal of neurology
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
6. The gain of6. function SCN1A disorder spectrum- novel epilepsy phenotypes and therapeutic implications.pdf
Size:
1.55 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: